- Home
- BCG vs INMB Comparison
BCG vs INMB Comparison
Compare BCG & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | INMB |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | 150 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6M | 34.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BCG | INMB |
|---|---|---|
| Price | $1.89 | $1.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | ★ 745.8K | 277.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $1.36 | $1.09 |
| 52 Week High | $3.44 | $11.64 |
Technical Indicators
Market Signals| Indicator | BCG | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 55.86 |
| Support Level | $1.46 | $1.40 |
| Resistance Level | $2.15 | $1.48 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 32.35 | 71.25 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.